Mericitabine

DB12045InvestigationalSmall molecule

Mericitabine has been investigated for the treatment of Hepatitis C, Chronic. Mericitabine is a polymerase inhibitor being developed for the treatment of chronic hepatitis C. Mericitabine is a prodrug of... Mericitabine is a prodrug of PSI-6130, which demonstrated excellent potency in preclinical studies.

Mechanism: Pharmacologically active on RNA-directed RNA polymerase
Curator reviewed
Formula / weight: C₁₈H₂₆FN₃O₆ · 399.419 g/mol (avg)
Code names: 3',5'-DIISOBUTYRYL PSI 6130 · PSI 6130 DIISOBUTYRATE · R-7128 · RG 7128 · RO-5024048

Resolves to

Compound

UNIITA63JX8X52CAS940908-79-2ChEMBLCHEMBL562967PubChem16122663

Structure

InChIKeyMLESJYFEMSJZLZ-MAAOGQSESA-NSMILESCC(C)C(=O)OC[C@H]1O[C@@H](N2C=CC(N)=NC2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C

Targets

O39930NS5bP26664Genome polyprotein

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Mericitabine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account